![conference banner](/images/conference-banner.jpeg)
Abstract
Alzheimers disease (AD) is the most common neurodegenerative disease in the developed world. The increasing life expectancy in the last years has led to an increase in the prevalence of this age-related condition and has posed an important medical and social challenge for developed societies. The mainstays of current therapy for AD rely on the cholinergic hypothesis developed more than 20 years ago. These compounds, known as acetylcholinesterase inhibitors (AChEIs), inhibit the cholinesterases and aim at improving the brain synaptic availability of acetylcholine. These drugs have been approved for the treatment of AD based on pivotal clinical trials showing modest symptomatic benefit on cognitive, behavioral, and global measures. Memantine, an NMDA antagonist, has been recently included as a therapeutic option for AD. Memantine can be combined safely with AChEIs for an additional symptomatic benefit. During the last years our understanding of the mechanisms underlying the pathogenesis of AD has markedly expanded. Several putative neuroprotective drugs are thoroughly investigated and many of them have reached the clinical arena. It can be anticipated that some of these drugs will be able to slow/prevent the progression of this condition in the near future.
Keywords: Treatment, Alzheimer's, acetylcholinesterase inhibitors, memantine, amyloid, behavioral symptoms, vitamin E, anti-inflammatory drugs
Current Genomics
Title: Current Therapeutic Options for Alzheimers Disease
Volume: 8 Issue: 8
Author(s): Alberto Lleo
Affiliation:
Keywords: Treatment, Alzheimer's, acetylcholinesterase inhibitors, memantine, amyloid, behavioral symptoms, vitamin E, anti-inflammatory drugs
Abstract: Alzheimers disease (AD) is the most common neurodegenerative disease in the developed world. The increasing life expectancy in the last years has led to an increase in the prevalence of this age-related condition and has posed an important medical and social challenge for developed societies. The mainstays of current therapy for AD rely on the cholinergic hypothesis developed more than 20 years ago. These compounds, known as acetylcholinesterase inhibitors (AChEIs), inhibit the cholinesterases and aim at improving the brain synaptic availability of acetylcholine. These drugs have been approved for the treatment of AD based on pivotal clinical trials showing modest symptomatic benefit on cognitive, behavioral, and global measures. Memantine, an NMDA antagonist, has been recently included as a therapeutic option for AD. Memantine can be combined safely with AChEIs for an additional symptomatic benefit. During the last years our understanding of the mechanisms underlying the pathogenesis of AD has markedly expanded. Several putative neuroprotective drugs are thoroughly investigated and many of them have reached the clinical arena. It can be anticipated that some of these drugs will be able to slow/prevent the progression of this condition in the near future.
Export Options
About this article
Cite this article as:
Lleo Alberto, Current Therapeutic Options for Alzheimers Disease, Current Genomics 2007; 8 (8) . https://dx.doi.org/10.2174/138920207783769549
DOI https://dx.doi.org/10.2174/138920207783769549 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Related Journals
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD): An Update [1]
Medicinal Chemistry Reviews - Online (Discontinued) The GSTM1 and GSTT1 Null Genotypes Increase the Risk for Type 2 Diabetes Mellitus and the Subsequent Development of Diabetic Complications: A Meta-analysis
Current Diabetes Reviews The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Vital Role of Monoamine Oxidases and Cholinesterases in Central Nervous System Drug Research: A Sharp Dissection of the Pathophysiology
Combinatorial Chemistry & High Throughput Screening Synthesis and Biological Evaluation of 2-Amino-1-phenyl-benzimidazole Derivatives as BACE1 Inhibitors
Letters in Drug Design & Discovery Emerging Role for αB-Crystallin as a Therapeutic Agent: Pros and Cons
Current Molecular Medicine Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer’s Disease
Current Alzheimer Research Subject Index to Volume 10
Current Pharmaceutical Design Cytosolic Phospholipase A2 Inhibitors as Therapeutic Agents for Neural Cell Injury
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Medial Temporal Lobe Volumes in Amnestic Mild Cognitive Impairment and Late-life Depression: Research Synthesis
Current Psychiatry Reviews Editorial: Advances in Alzheimer Therapy: Something Old, Something New, Something Borrowed, Something Blue
Current Alzheimer Research Cognitive Impairment in Systemic Lupus Erythematosus: Prevalence and Clinical Importance
Current Rheumatology Reviews New Approaches in Nuclear Medicine for Early Diagnosis of Alzheimers Disease
Current Alzheimer Research Non-Analgesic Effects of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update.
Current Pharmaceutical Design Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Exploring the Benefits of Cellular Models to Uncover Bioactive Polyphenols for Neurodegeneration
Current Pharmaceutical Design Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal Progression of Alzheimer's Disease
Current Alzheimer Research